Nektar Therapeutics (NKTR) Looks Good: Stock Up 6.8% in Session

Zacks Equity Research

Nektar Therapeutics (NKTR) was a big mover last session, as the company saw its shares rise nearly 7% on the day. This jump can be attributable to solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company, as the stock is now up 55.7% in the past one-month time frame.

In the last 30 days, this company did not witness any estimate revisions and the Zacks Consensus Estimate has remained unchanged. However, yesterday’s price action is encouraging, so make sure to keep a close watch on this firm in the near future.

Nektar Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Some better-ranked med drug stocks include DepoMed Inc. (DEPO), Endocyte, Inc. (ECYT) and Lannett Company, Inc. (LCI). All these stocks hold a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

NEKTAR THERAPEUTICS (NKTR): Free Stock Analysis Report

LANNETT COMP (LCI): Free Stock Analysis Report

DEPOMED INC (DEPO): Free Stock Analysis Report

ENDOCYTE INC (ECYT): Free Stock Analysis Report

Zacks Investment Research